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In order progressively to establish the free movement of proprietary medicinal 
prod~ctsp the Council has·adopted four Directives1 essentially relating_ to 
the conditions in which the Member States deLiver marketing authori~ations 
for these products. 
Furthermore, in the "De Peijper" case"2; the .Court of Justice of the European· 
Communities, to which the matter was referred under Article '177 of the EEC 
Treaty, has delivered a judgment on l?arallel imports o·f medicinal products. 
This judgment gives the Commission interpretative rulings enabling it to 
exercise more stringent checks on the application of the rules of the Treaty 
on free movement of goods, in particular the provisions of Articles '30-36 of 
the EEC Treaty. .. 
Following this judgment, the Commission considered it necessary to supplement 
the existing Directives by transmitting to the.Council on 2 June 1980 a 
proposal for a Directive3 relating to para.Llel imports of proprietary 
medicinal products. 
'· 
1 Direct~ve 65/65/EEC of 26 January 1965, OJ No 22, 9.2.1965 
Directive 75/318/EEC of 20 Nay 1975, OJ L 147,. 9.6.1975 
Directive 75/319/EEC of 20 May 1975, OJ L 147,. 9.6.1975 
Directive 78/25/EEC of 12 December .1977F OJ L '11, 14.1.1978 
2 CJEC 20 May 1976, case 104/75p 1976 Report, p':, 6'l:;i . 
./. 
3Proposal dated 2 June 1980 for a Directive amenqing Directives 65/65/EEC 
and 75/319/EEC, OJ C 143, j2.6.1980. 
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The commission has taken note of t~e objections raised by the Economic and 
Socinl Committee to the proposal relating to parallel imports and the 
negative vote taken on that proposal by the European Parliament on 16 October 
1981. 
The Commission has therefore decided to withdraw its proposal; especially as 
its adoption by the Council appears improbable in the present circumstances. 
The Commission is not, however, aba0doning its responsibility to ensure that 
full effect is given to the provisions of the Treaty relating to the free· 
movement of goods. The Parliament stressed during its discussion and in the 
text of its Resolution its attachment to the principle of free movement. This 
is why the Commission wishes-to indicate, on the occasion of this withdrawal, 
the way in which it intends to apply, under its own responsibility, the 
rules embodied in the Treaty as interpreted by the Court of Justice, in order 
to preserve the unity of the Community's internal market. 
* 
* * 
.1. 
1 
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In case 104/75, the ~ourt had.to give a ruling on a set of he~Lth regulations 
relating to the marketing of medicinal products that prevented the marketing 
of a medicinal product introduced as a paraLLeL import.· 
·' 
rules or practices which 
.. 
The Court first of all established that national 
result in imports being channelled in such a way that only certain traders-
can effect these imports, whereas others are prevented from· doing so, are , • 
caught by thi prohibition set out jn Article 30 of the EEC Treaty. 
' The Court went on to reaffirm the Member States' right, in pursuance of 
Article 36 of the EEC Treaty, to decide, subject to_the Limitations imposed 
by the Treaty, 'on t.he Level of protection they wish to afford for the 
health and Life of persons, in particular the stringency of the checks to 
be ea rri ed outo 
It nevertheless immediately stressed the general context in which this 
competence of the Member States was to be exercised: 
"National rules or practices Hhich do restrict imports of pharmaceutical 
products or are capable of doing so are only compatible with the Treaty to 
the extent to which they are necessary for the effective protection of heal~h 
and Life of humans~ 
National rules or practices do not fall within the exception specified in 
Article 36 if the health and ~ife of humans can be as effectively protected 
by measures which do not restrict intra-Community trade so much. 
,·, 
In particular Article 36 cannot be relied on to justify rul~s or practices· 
which, even though they are beneficial, contain restrictions which are 
explained primarily by a concern to Lighten the administration's burden or 
reduce public expenditure, unless, in the absence of the said rules or 
practices, this burden or expenditure clearly would exceed the Limits of 
what can reasonably be required." 
.I. 
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' In the case in poin , the competent nat:io11al authodties intended to prevent 
a paraLLel impo1·ter ·f1·om marketing a medicinal product that was similar to 
a medicinal product _which had already been authorized and was pr-oduced by .. 
I 
I the same. manufacturer~ for t~1o reasons. 
First, the parallel manufacturer was not able to provide the authorities 
with the complete file1 relating to the quality, efficacy and safety of 
. 
the product in general, which the, manufacturer's authorized importer had 
already supplied to those same.authoriti~s with a view to obtaining a 
marketing authorization for that medicinal product. 
. ' 
Secondly, the parallel importer could not, 
obtain from the manufacturer the reports on 
turing batch. 
• • • £~ 
unlike the authorized importer, 
checks made on each manufac-
. I 
' 
In the judgment on the "De Pei jper" case, the Court ruled that 
"national rules or practices which make it possible for a manufacturer of 
the pharmaceutical 
simply by refusing 
product in question and his duly appointed representative, 
" to produce the documents relating to the medicinal 
preparation in general or to a specific batch of that preparation, to 
enjoy a monopoly of the importing and marketing of the product, must 
be regarded·as being unnecessarily restrictive, unless it is clearly proved 
that any other rules or practices would obviously be_ beyond the ·means which 
can be reasonably expected of an administration operating in a normal 
manner ••• " 
"It is only if the information or documents to be produced by the manu-
facturer or his duly appointed importer show that there are several 
variants of the medicinal preparation and that the differences between 
these variants have a therapeutic effect that there would be any justifi-
cation for treating the variants as different medicinal preparations, 
for the purpose of authorizing them to be placed on the market and as 
regards producing the relevant documents ••• ". 
* 
* * 
1 This file comprises, inter alia, a description of the manufacturer's 
production and control methods and the results,of the analytical, 
toxico-pharmacological and clinical tests conducted on·the medicinal 
product in general. 
! 
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! 
The Commission, in its\ roLe 
rules and practices applied 
as guardian of tha Treaty, wiLL epsure ~hat the 
' by Member States to parallel imports of medicinal 
- - ·~ 
products, and'in particular proprietary medicinal products which account for 
the majority of intra-fommunity tr.ading operations in medicinaL pr~ducts, 
will remain within limits compatible with Articles 30-36. 
In particular, such measures must: 
- be strictly neces~ary from the health standpoint, 
- obstruct intra-Community trade as little as possible, 
- require the Membe~ States to adopt an active and vigilant attitude towards 
pharm~ceutical companies. 
The Commission points out that the competent authorities in the Member States 
are not entitled to oppose the marketing of any medicinal product, the subject 
of parallel importation, that already has a marketing authorization, on the 
grounds that the parallel importer is not able to obtain documents which 
only the manufacturer or his approved representative can have at their 
disposaL. 
In the absence of any hat·monized rules governing the system of parallel 
imports, it is up to the Commission, in accordance with the procedure under 
Article 169, and to the ·interested parties, in accor_dance with the means of 
redress which they have at their disposal, to ensure that parallel imports 
of medicinal products are made possible under the conditions Laid down by 
the rulings of the Court. 
After consulting senior experts in public health matters from the Member 
States' administrations meeting in the Pharmaceutical Committee1,·the 
Commission had proposed ~ uniform system for parallel imports of proprietary 
medicinal products. Despite the withdrawal of its proposal, the Commission 
considers it useful to indicate save ways of monitoring parallel imports 
which, subject to the rulings of the Court, seem to ~it to be justified for 
the purpose of protecting the health and Life of humans pursuant to 
Article 36 of the Treaty. 
.I. 
1 Set up by Council Decision 75/320/EEC of 20 May 1975, OJ L 147, 9.6.1975. 
I 
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' 
already have at their disposal two important safeguards for health in the 
case of parallel imports of proprietary medicinal products. 
On the one hand, the national rules governing the activities of importers, 
wholesalers and, where applicable, manufacturers of proprietary medicinal 
products apply equally to parallel importers. These rules usually cover 
professional competence and responsibilities, the technical premises and 
equipment requir~d and the rules for the operation of such establishments, 
. . 
in particular the procedures relating to the preservation of documents to 
facilitate official checks and inspections. 
On the other hand, the authorities competent to issue marketing authorizations 
for proprietary medicinal products already, as a rule, possess the dossier 
relating to the quality, efficacy and safety of the medicinal product in 
general, which has been supplied by the manufacturer or his approved importe~ 
and which states, in pursuance of Article 4(11) of Directive 65/65/EEC, 
the authorizations already obtained for the product in any other Member 
State. According to the Court, the competent administration of the importing 
M.ember State is clearly; entitled to require the manufacturer, or his duly. 
appointed importer, to ftate whether the manufacturer,or the group of manu-
facturers to which he b~longs, produces several variants of the same 
' medicinal product for different Member States. If this is so, it is only if 
the documents submitted by the manufacturer show that there are differences 
having a therapeutic effect that there would be any justification for 
treating the variants as different medicinal products for the purpose of 
marketing authorization. 
In addition to these safegua1·ds, the authorities have a Legitimate interest 
' in being'able to verify, at all times and beyond doubt, whether the batches 
of imported medicinal products are in conformity with the particulars 
contained in the dossier. 
'~ 
.. 
J 
.!. 
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Th~ Commission concedes that the parallel importer may be req~ired to supply 
the competent authorities in the Member State into which the product is 
imported with certain information readily accessible to him when he wants 
to market for the first time a proprietary medicinal product already marketed 
by the manufacturer or his duly appointed representative •. 
This information must allow the competent authorities in the Member State 
into which the product is imported to check, within a reasonable period, 
that the proprietary medicinal product that is the subject of parallel 
imp~rtation is eff~ctively covered by the ~arketing authorization already 
granted to the·manufacturer or his duly appointed representative. ln the 
Commission's view, this period should not exceed 45 days from the time the 
parallel importer gives the following information to the competent 
authorities: 
(a) name of the proprietary medicinal product in the Member State into which 
it is imported and in the Member State from which it comes; 
(b) name or corporate name and permanent address of the person responsible 
for placing the product on the market in the Member State into which 
it is ·imported and in the Member State from 11hi eh it comes, and LoJhere 
appropriate, of the manufacturer(s); 
(c) name or corporate name and permanent address of the parallel importer; 
(d) numbers of the marketing authorizations in the Member State into which 
the product is imported and in the Member State from which it comes; 
(e) any other general 
medicinal product 
information useful for the marketing of the proprietary 
in the Member State into whi eh it is imported, i:.e. ,. 
-qualitative and quantitative composition in terms of active principles, 
by dosage unit or in percentage, using the international non-proprietary 
names recommended by the World Health Ot•ganisation where such names 
exist, 
pharmaceutical fo~m and route of administration, 
-therapeutic indications and normal dosage, 
.!. 
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- contra-indications and main side-effects 
- storage precauti ens, if any; 
I (f) one or more specimens or mock-ups of the proprietary product in the form 
To 
in which it will be marketed in the Member State into which it is imported, 
including the package Leaflet, if any. 
enable the authorities to be effectively informed of the marketing of each 
batch of the product imported, the parallel importer should, in the Commis-
sion's view, register the origin, quantity and batch numbers of the imported 
medicinal products whenever he imports them, and hold this information at 
the disposal of the competent authorities. 
The Commission points out that pursuant to Chapter IV of Directive 75/319/EEC 
each bat eh of proprietary medicinaL products manufactured in a Member State 
is checked by the manufacturer who makes out a certificate and registers the 
operations carried out in documents that remain at the disposal of the 
agents of the competent authority for at Least five years. Because these~ 
control reports are sent to him by the manufacturer, the.duly appointed 
importer is exempt from repeating the controls in the Member State. into which 
the product is imported. 
Since the parallel importer does not have access to these control reports, 
the national authorities have to adopt a more active policy when they wish 
to verify the controls carried cui by the manufacturer on a given batch. 
They can choose for this purpose one of the four approaches given in the 
De Peijper judgment, i.e.: 
- they can obtain the manufacturing control reports by taking Legislative or 
administrative measures compelling the manufacturer himself, or his duly 
appointed representative, to supply them; 
they can obtain these reports through the authorities in the country of 
manufacture; 
- they can, whenever possible, Lay down a presumption of conformity with the 
specifications of the medicament and it would be up to them,. in appropriate 
cases, to rebut this presumption after verification of the conformity; 
- as far as this presumption is fully impractibable, they can allow the 
parallel importer to provide proof of conformity by any means other than 
by documents to which he has no access. 
./. 
l 
l 
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The parallel importer is Liable, in the same way as the person .responsible 
for marketing, to the measures taken by the Member States to withdraw the 
product, to suspend or revoke the authorization or to prohibit Slipply of 
' the product, pursuant to Article 28 of Di recti've 75/319/EEC. 
) 
* 
* * 
By appropriate cooperation between the Member State authorities, it would 
' c 
be possible to supplement, if necessary, the monitoring measures compatible· 
with Article 36 of the Treaty, designed to check the conformity of medicinal 
products imported in parallel. 
In the De Peijper judgment, the Court held that simple cooperation betv1een 
the authorities of the Member States would enable them to obtain on a 
reciprocal basis the documents necessary for checking certain Largely 
standardized and widely distributed products • 
In addition to the obligations resulting from Article 5 of the EEC Treaty, 
the obligation for the competent authorities to communicate to each other 
such information as is appropriate to guarantee that the requirements for 
' the marketing or manufacturing authorizations are fulfilled is specificaLLy-
speLLed out in Article 30 of Directive 75/319/EEC. 
The Commission for its part is prepared to do everything it can to assist 
the Member States in exchanging the information they consider necessary to 
. . 
check the conformity of parallel imports of proprietary medicinal products • 
• 1. 
.· 
"'-
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The Commission considers that the Committee for Proprietary Medicinal Products, 
set up by Directive 75/319/EEC, provides a suitable forum for any exchanges 
of information between the representatives of the Member States responsible 
for marketing authorizations for proprietary medicinal products. The Commission 
also holds at the disposal of Member States a continuously updated list of 
the persons appointed by the competent authorities to supply at short notice 
any necessary information on marketing or manufacturing authorizations in 
application of Articles 30 and 33 of Directive 75/319/EEC. 
* 
* * 
~-
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